Abstract
Background: This study investigated whether rosiglitazone might affect dementia risk. Methods: The Taiwan’s National Health Insurance database was used to enroll a cohort of 1:1 matched-pairs of ever and never users of rosiglitazone based on propensity score from patients with new onset type 2 diabetes during 1999-2006. The patients were alive on January 1, 2007 and were followed-up for dementia until December 31, 2011. Results: A total of 5048 pairs of never users and ever users were identified. The incident case numbers were 127 and 121, respectively. The overall hazard ratio was 0.895 (95% confidence interval: 0.696-1.151) for ever versus never users. The hazard ratios for the first (<12.1 months), second (12.1-25.1 months) and third (>25.1 months) tertiles of cumulative duration were 0.756 (0.509-1.123), 0.964 (0.685-1.357) and 0.949 (0.671-1.341), respectively. When cumulative duration was treated as a continuous variable, the hazard ratio was 1.000 (0.992-1.008). Subgroup analyses conducted in ever users and never users of metformin and in patients whose diabetes was diagnosed during three different periods of time, i.e., 1999-2000, 2001-2003 and 2004-2006, all supported a neutral effect of rosiglitazone. Conclusions: Rosiglitazone has a neutral effect on dementia risk in patients with type 2 diabetes mellitus. Disclosure C. Tseng: None.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
